Forløb af ordinær generalforsamling den 17. april 2024 i Investeringsforeningen C WorldWide
Dagsordenens pkt. 1) Bestyrelsens beretning for det forløbne regnskabsår
Bestyrelsens beretning blev taget til efterretning af generalforsamlingen.
Dagsordenens pkt. 2) Fremlæggelse af årsrapport til godkendelse, forslag til anvendelse af årets resultat, forslag til anvendelse af provenu ved formuerealisationer samt godkendelse af bestyrelsesmedlemmernes honorar
Årsrapporten for 2023, herunder forslag til udlodning og bestyrelsens honorar, blev enstemmigt godkendt.
Udbytterne for de noterede afdelinger og andelsklasser udgør nedenstående beløb for regnskabsåret 2023:
| Afdeling/andelsklasse | Navn | kr. pr. andel |
| DK0010157965 | Globale Aktier KL A | 77,10 kr. |
| DK0060287217 | Globale Aktier Etik KL Udl | 14,10 kr. |
| DK0010312529 | Stabile Aktier KL A | 0,00 kr. |
| DK0060057644 | Asien KL A | 0,00 kr. |
| DK0015945166 | Emerging Markets KL | 0,00 kr. |
| DK0061534963 | Indien KL A | 0,50 kr. |
Dagsordenens pkt. 3) Decharge til bestyrelsen
Generalforsamlingen meddelte decharge til bestyrelsen.
Dagsordenens pkt. 4) Forslag fremsat af investorer eller bestyrelsen
Ingen forslag var fremsat.
Dagsordenens pkt. 5) Valg af medlemmer til bestyrelsen
Alle bestyrelsens medlemmer var på valg. Karsten Kielland og Camilla Hartvig havde valgt ikke at genopstille. Christoffer Fode, Lars Aaen og Lone Dencker Wisborg blev genvalgt. Bestyrelsen består herefter af Christoffer Fode, Lars Aaen og Lone Dencker Wisborg.
Bestyrelsen konstituerede sig efterfølgende med Christoffer Fode som formand.
Dagsordenens pkt. 6) Valg af revisor
EY Godkendt Revisionspartnerselskab blev genvalgt som foreningens revisor.
Med venlig hilsen
Investeringsforeningen C WorldWide
Henrik Brandt
Direktør
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
New number of votes and shares outstanding30.4.2024 10:00:00 CEST | Press release
Where the company increases or reduces the total number of shares or votes in the company, the company shall by law publish information regarding the change. At the 2011 Annual General Meeting, a share conversion clause was added to Industrivärden’s articles of association. Shareholders have the right at any time to request conversion of Class A shares to Class C shares. During the month of April 2024, 3,104,052 Class A shares were converted to 3,104,052 Class C shares. Following the share conversion, the number of votes in the company is 263,396,693.5. The total number of registered shares in the company is 431,899,108, of which 244,674,203 are Class A shares and 187,224,905 are Class C shares. Stockholm, April 30, 2024 AB INDUSTRIVÄRDEN (publ) For further information, please contact: Sverker Sivall, Head of Corporate Communications and Sustainability, tel. +46-8-666 64 00 This information is information that AB Industrivärden is obliged to make public pursuant to the Financial Instru
Ekstraordinære indfrielser (CK93)30.4.2024 10:00:00 CEST | pressemeddelelse
KommuneKredit offentliggør hermed oplysninger om ekstraordinære indfrielser (CK93) pr. 26. april 2024. Der er pr. opgørelsesdagen ingen ekstraordinære indfrielser. For yderligere informationer om dataformat og –indhold henvises til Nasdaqs hjemmeside. Med venlig hilsen KommuneKredit
One Za’abeel launches The Offices, Dual Licensed Office Space in One Za’abeel Tower30.4.2024 10:00:00 CEST | Press release
DUBAI, United Arab Emirates, April 30, 2024 (GLOBE NEWSWIRE) -- One Za’abeel, the iconic mixed-use development developed by ICD (Investment Corporation of Dubai), is pleased to announce the launch of The Offices, its ultra-luxurious dual licensed corporate office spaces in One Za’abeel Tower. The Grade-A offices are set to become Dubai’s ultimate business address, attracting global and local organisations alike with its unique dual licensing for both Dubai World Trade Centre Free Zone (DWTC FZ) registered companies and those registered under the mainland. One Za’abeel is comprised of two skyscrapers, One Za’abeel Tower and One Za’abeel The Residences, which are dissected by The Link, a 230m cantilevered building suspended 100 meters above the ground. The unique shape of the mixed-use development, coupled with its strategic location, garnered it the nickname “The Gateway to Dubai’s Central Business District.” The Offices occupy 17 levels in One Za’abeel Tower and cover a total area of 2
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)30.4.2024 10:00:00 CEST | Press release
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva PharmaceuticalsThe high-concentration interchangeable biosimilar to Humira® manufactured by Alvotech will be distributed under Quallent’s private-label REYKJAVIK, ICELAND, PARSIPPANY, N.J., and TEL AVIV, ISRAEL (April 30, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), disclosed today that under the recently announced U.S. strategic partnership agreement, Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals in alignment with its U.S. commercialization agreement with Teva. The inte
Nytt antal röster och utestående aktier30.4.2024 10:00:00 CEST | Pressemelding
Bolaget har en skyldighet enligt lag att offentliggöra uppgifter om en förändring i totala antalet aktier eller röster i bolaget. Vid årsstämman 2011 infördes ett omvandlingsförbehåll i Industrivärdens bolagsordning. Aktieägare har rätt att när som helst begära omvandling av A-aktier till C-aktier. Under april månad 2024 har omvandlingar skett av 3 104 052 A-aktier till 3 104 052 C-aktier. Efter omvandlingen uppgår antalet röster i bolaget till 263 396 693,5. Det totala antalet registrerade aktier i bolaget uppgår till 431 899 108, varav 244 674 203 A-aktier och 187 224 905 C-aktier. Stockholm den 30 april 2024 AB INDUSTRIVÄRDEN (publ) För ytterligare information kontakta: Sverker Sivall, Kommunikations- och hållbarhetschef, tel. 08-666 64 00 Denna information är sådan information som AB Industrivärden är skyldigt att offentliggöra enligt lagen om handel med finansiella instrument. Informationen lämnades, genom kommunikations- och hållbarhetschefen Sverker Sivalls försorg (tel. 08-666